Learning points:
-It is helpful to
begin generating a differential diagnosis immediately upon hearing the “chief
complaint.” This will help frame the
questions that you are going to ask, and even frame the way that you obtain the
past medical history. As an example, if
this patient had come in with an allergic reaction, his COPD severity is less
important in the clinician’s mind than it is when he presents with dyspnea and
fever.
-When evaluating
patients, always obtain their medical
history and the medications that they take.
There is a large prescribing bias towards keeping people on what they
were on, even though many clinicians would advocate for stopping medications
that we cannot identify a good cause for – examples frequently include
proton-pump inhibitors, iron supplementation, cholesterol medications in the
frail elderly, dual antiplatelet therapy, etc.
If their medical history does not match up to their medications, our job
is to make a reasonable attempt at correcting that.
-Patients with lung
cancer who present with dyspnea are usually going to have one of four things:
consolidated lung (pneumonia), bronchial obstruction, pleural effusion, and
pneumothorax.
-Fever can be present
in these patients for a variety of reasons including as a result of the tumour
itself. That said, in the case of a
fever with a consolidated lung as a result of obstruction, treatment with
antibiotics may be warranted after obtaining cultures.
-Treatment of lung
cancer is rarely with a curative intent.
We talked about the types of lung cancer (small cell and non-small cell)
and that small-cell generally portends a worse diagnosis. Treatment options for these patients can
include simple interventions like palliative oxygen. Systemic treatments like chemotherapy and
steroids (in the right setting) may alleviate or shrink tumours and re-open
airways. Radiation is another option
that may have relatively minor risks.
Finally, thoracic surgery can occasionally “stent” open airways as a
result of tumours, but they are relatively selective to whom they offer this.
Resources for further reading:
Hsu-Kim, C., Hoag, J. B., Cheng, G. S., & Lund, M. E. (2013). The Microbiology of Postobstructive Pneumonia in Lung Cancer Patients. Journal of bronchology & interventional pulmonology, 20(3), 266-270.
No comments:
Post a Comment